Program
telikibart
Its studies are mostly in Rhinitis, Allergic, Seasonal · Nasal Polyps · Rhinitis, Allergic · Asthma · Dermatitis, Atopic, led by Chongqing Genrix Biopharmaceutical.
Furthest: phase 3, since Jan 11, 20247 company-led studies, 7 open or runningNext primary completion: May 15, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Genrix Biopharmaceutical | 77 open or running | phase 3since Jan 11, 2024 | May 16, 2023 | May 15, 2027phase 3 · NCT07199257 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 16, 2023First study: phase 2 study in Chronic Rhinosinusitis with Nasal PolypsFirst studyNCT05873803 · 70 enrolled · China
- Aug 15, 2023Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06015243 · 70 planned
- Jan 11, 2024Phase 3 study in Dermatitis, AtopicNCT06216392 · 450 planned · China
- Mar 11, 2024Phase 2 study in Rhinitis, AllergicNCT06315426 · 240 enrolled · China
- Oct 14, 2024Phase 2 study in AsthmaNCT06642961 · 150 planned · China
- Aug 13, 2025Phase 3 study in Rhinitis, Allergic, SeasonalNCT07154342 · 150 planned · China
- Sep 22, 2025Phase 3 study in Rhinitis, Allergic, SeasonalNCT07199257 · 144 planned · China
Ahead
- May 15, 2027Primary completion: phase 3 study in Rhinitis, Allergic, SeasonalNCT07199257
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07199257Rhinitis, Allergic, Seasonal · China | 3 | Not yet recruiting | May 15, 2027 | 144 |
| NCT07154342Rhinitis, Allergic, Seasonal · China | 3 | Recruiting | Apr 30, 2026 | 150 |
| NCT06642961Asthma · China | 2 | Recruiting | Mar 31, 2025 | 150 |
| NCT06315426Rhinitis, Allergic · China | 2 | Active, not recruiting | May 2025 | 240 |
| NCT06216392Dermatitis, Atopic · China | 3 | Not yet recruiting | Jun 2025 | 450 |
| NCT06015243Chronic Rhinosinusitis With Nasal Polyps | 2 | Not yet recruiting | Dec 30, 2024 | 70 |
| NCT05873803Chronic Rhinosinusitis with Nasal Polyps · China | 2 | Active, not recruiting | Oct 30, 2024 | 70 |
How it is read
Names in the registry
- “GR1802 injection”, 8 entries
Conditions, from the studies’ own filings
- Rhinitis, Allergic, Seasonal, 2 studies
- Nasal Polyps, 2 studies
- Rhinitis, Allergic, 1 study
- Asthma, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.